Joincare (Joincare Pharmaceutical Group Industry Co., Ltd) is headquartered in Shenzhen. After years of steady operation and rapid development, it has now become an innovative and scientific research-oriented comprehensive pharmaceutical group. The company has always adhered to technological innovation as its strategic basis, and its strategic goal is to build a high-barrier complex preparation technology platform. Currently, it has deployed four high-barrier complex preparation R&D platforms. It owns two large listed companies of Joincare and Livzon Pharmaceutical, more than 20 major holding subsidiaries, and currently employs nearly 13,000 people. As of the end of 2020, the company's total assets were 28.157 billion yuan and operating income was 13.522 billion yuan.
Joincare's COVID-19 vaccine booster that can effectively fight against Omicron is under application for marketingJoincare's COVID-19 vaccine booster that can effectively fight against Omicron is under application for marketing
The Inhale Preparation of Joincare is Listed in the Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease
Exploring the Blue Ocean Market of Inhalation Industry！Two Major Products Developed by Joincare Were Permitted to Produce
Action Speaks for Responsibility, Joincare Wins Best Social Responsibility Award of "China ESG Golden Awards 2020"
Joincare leads the breathing layout and releases intrinsic value, many institutions are optimistic about its future
The fifth session of Pengcheng Charitable Donation List was published, and Joincare’s Chairman Zhu Baoguo was selected into the personal list of charitable donation
Giving full play to the advantages of pharmaceutical health industry, Joincare has been awarded “Outstanding Contribution Award of Anti-epidemic”
SEARCH FOR THE PRODUCTS YOU NEED
Official WeChat Official Account